Loxo Oncology (NASDAQ:LOXO) VP Jennifer Burstein sold 1,700 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $131.33, for a total value of $223,261.00. Following the sale, the vice president now directly owns 1,700 shares in the company, valued at approximately $223,261. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Jennifer Burstein also recently made the following trade(s):
- On Monday, February 12th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The stock was sold at an average price of $93.24, for a total value of $158,508.00.
- On Tuesday, January 16th, Jennifer Burstein sold 1,500 shares of Loxo Oncology stock. The stock was sold at an average price of $87.50, for a total value of $131,250.00.
NASDAQ:LOXO traded down $2.33 on Friday, reaching $110.85. The company’s stock had a trading volume of 276,035 shares, compared to its average volume of 458,223. Loxo Oncology has a 12-month low of $42.11 and a 12-month high of $135.74. The company has a market capitalization of $3,329.27, a P/E ratio of -20.88 and a beta of 2.32.
Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million during the quarter. equities analysts expect that Loxo Oncology will post 0.3 EPS for the current year.
Several brokerages recently weighed in on LOXO. ValuEngine raised Loxo Oncology from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Morgan Stanley lowered Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price target on the stock. in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $148.00 price objective on the stock in a research note on Friday, March 9th. Citigroup reissued a “buy” rating and set a $151.00 price objective (up previously from $108.00) on shares of Loxo Oncology in a research note on Monday, March 5th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $135.00 price objective on shares of Loxo Oncology in a research note on Friday, March 2nd. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $124.44.
Several large investors have recently added to or reduced their stakes in LOXO. State Board of Administration of Florida Retirement System boosted its position in shares of Loxo Oncology by 16.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 9,760 shares of the biopharmaceutical company’s stock valued at $899,000 after purchasing an additional 1,400 shares during the period. New York State Common Retirement Fund raised its stake in Loxo Oncology by 2.9% during the 3rd quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock valued at $2,312,000 after acquiring an additional 700 shares during the last quarter. Rhumbline Advisers raised its stake in Loxo Oncology by 11.5% during the 3rd quarter. Rhumbline Advisers now owns 25,234 shares of the biopharmaceutical company’s stock valued at $2,325,000 after acquiring an additional 2,608 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Loxo Oncology by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 121,558 shares of the biopharmaceutical company’s stock valued at $11,198,000 after acquiring an additional 4,018 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Loxo Oncology during the 3rd quarter valued at approximately $212,000.
TRADEMARK VIOLATION NOTICE: “Loxo Oncology (NASDAQ:LOXO) VP Jennifer Burstein Sells 1,700 Shares” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/jennifer-burstein-sells-1700-shares-of-loxo-oncology-inc-loxo-stock.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.